An atlas of epithelial cell states and plasticity in lung adenocarcinoma
Author:
Han GuangchunORCID, Sinjab AnsamORCID, Rahal Zahraa, Lynch Anne M., Treekitkarnmongkol WarapenORCID, Liu YuejiangORCID, Serrano Alejandra G., Feng Jiping, Liang Ke, Khan Khaja, Lu Wei, Hernandez Sharia D., Liu YunheORCID, Cao XuanyeORCID, Dai Enyu, Pei Guangsheng, Hu Jian, Abaya Camille, Gomez-Bolanos Lorena I.ORCID, Peng Fuduan, Chen MinyueORCID, Parra Edwin R.ORCID, Cascone TinaORCID, Sepesi BorisORCID, Moghaddam Seyed JavadORCID, Scheet PaulORCID, Negrao Marcelo V.ORCID, Heymach John V.ORCID, Li MingyaoORCID, Dubinett Steven M.ORCID, Stevenson Christopher S., Spira Avrum E., Fujimoto JunyaORCID, Solis Luisa M.ORCID, Wistuba Ignacio I., Chen JichaoORCID, Wang LinghuaORCID, Kadara HumamORCID
Abstract
AbstractUnderstanding the cellular processes that underlie early lung adenocarcinoma (LUAD) development is needed to devise intervention strategies1. Here we studied 246,102 single epithelial cells from 16 early-stage LUADs and 47 matched normal lung samples. Epithelial cells comprised diverse normal and cancer cell states, and diversity among cancer cells was strongly linked to LUAD-specific oncogenic drivers. KRAS mutant cancer cells showed distinct transcriptional features, reduced differentiation and low levels of aneuploidy. Non-malignant areas surrounding human LUAD samples were enriched with alveolar intermediate cells that displayed elevated KRT8 expression (termed KRT8+ alveolar intermediate cells (KACs) here), reduced differentiation, increased plasticity and driver KRAS mutations. Expression profiles of KACs were enriched in lung precancer cells and in LUAD cells and signified poor survival. In mice exposed to tobacco carcinogen, KACs emerged before lung tumours and persisted for months after cessation of carcinogen exposure. Moreover, they acquired Kras mutations and conveyed sensitivity to targeted KRAS inhibition in KAC-enriched organoids derived from alveolar type 2 (AT2) cells. Last, lineage-labelling of AT2 cells or KRT8+ cells following carcinogen exposure showed that KACs are possible intermediates in AT2-to-tumour cell transformation. This study provides new insights into epithelial cell states at the root of LUAD development, and such states could harbour potential targets for prevention or intervention.
Publisher
Springer Science and Business Media LLC
Reference67 articles.
1. Kadara, H., Scheet, P., Wistuba, I. I. & Spira, A. E. Early events in the molecular pathogenesis of lung cancer. Cancer Prev. Res. 9, 518–527 (2016). 2. Cardarella, S. & Johnson, B. E. The impact of genomic changes on treatment of lung cancer. Am. J. Respir. Crit. Care Med. 188, 770–775 (2013). 3. Timar, J. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. Curr. Opin. Oncol. 26, 138–144 (2014). 4. Tomasini, P., Walia, P., Labbe, C., Jao, K. & Leighl, N. B. Targeting the KRAS pathway in non-small cell lung cancer. Oncologist 21, 1450–1460 (2016). 5. Kadara, H. et al. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J. Natl Cancer Inst. 106, dju004 (2014).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|